Return to search

Athira Pharma snags $85m Series B

Seattle-based Athira Pharma Inc, a developer of regenerative therapies focused on restoring brain function, has closed $85 million in Series B financing.

Seattle-based Athira Pharma Inc, a developer of regenerative therapies focused on restoring brain function, has closed $85 million in Series B financing. Perceptive Advisors led the round. In connection with the financing, Joseph Edelman, CEO and portfolio manager of Perceptive Advisors, will join Athira Pharma’s board of directors.

Source: Press Release